Acalabrutinib in Combination with ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Trial Identifier:	ACE-CL-002
Sponsor:	AcertaPharma
NCTID::	NCT02157324
Start Date:	August 2014
Primary Completion Date:	July 2020
Study Completion Date:	December 2025
Condition:	CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
US, OH	Columbus, OH, US, 43210
US, TN	Hermitage, TN, US, 37076
US, TX	Fort Worth, TX, US, 76104

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.